Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

In Partnership With:

Partner | Cancer Centers | <b>The Tisch Cancer Institute</b>

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

Matthew Galsky, MD, professor of medicine (hematology and medical oncology), professor of urology, director, Genitourinary Medical Oncology, co-director, Center of Excellence for Bladder Cancer, associate director, Translational Research, The Tisch Cancer Institute, Mount Sinai, discusses clinical trials that addressed key questions in urothelial cancer.

The phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials addressed the question of whether chemotherapy should be given in combination with checkpoint inhibitors in the treatment of patients with metastatic urothelial carcinoma. Additionally, IMvigor130, KEYNOTE-361, as well as the phase 3 DANUBE trial (NCT02516241) answered the question of whether checkpoint inhibitors should be given alone compared with chemotherapy in this patient population.

The DANUBE trial also evaluated whether a PD-L1 inhibitor should be given in combination with a CTLA-4 inhibitor in patients with metastatic urothelial carcinoma, Galsky explains. Finally, the phase 3 JAVELIN Bladder 100 trial (NCT02603432) evaluated the utility of switch maintenance therapy with avelumab (Bavencio) in patients who derived at least stable disease with up-front chemotherapy in this patient population, Galsky concludes.